A Novel Allogeneic Rituximab-Conjugated Gamma Delta T Cell Therapy for the Treatment of Relapsed/Refractory B-Cell Lymphoma

SIMPLE SUMMARY: CD20-targeting CAR T cells have shown remarkable clinical outcomes in patients with B-cell malignancies. However, the manufacturing processes usually involved in autologous cell collection and gene editing limit their usage and development across the board. Here, we developed an allo...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Hao-Kang, Wu, Tai-Sheng, Kuo, Yi-Chiu, Hsiao, Ching-Wen, Yang, Hsiu-Ping, Lee, Chia-Yun, Leng, Pei-Ju, Chiang, Yun-Jung, Cheng, Zih-Fei, Yang, Sen-Han, Lin, Yan-Liang, Chen, Li-Yu, Chen, Ciao-Syuan, Chen, Yu-Ju, Hsiao, Shih-Chia, Tang, Sai-Wen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10571679/
https://www.ncbi.nlm.nih.gov/pubmed/37835538
http://dx.doi.org/10.3390/cancers15194844

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10571679/
https://www.ncbi.nlm.nih.gov/pubmed/37835538
http://dx.doi.org/10.3390/cancers15194844

Ejemplares similares